Targeting HMGA protein inhibits retinoblastoma cell proliferation

Akilandeswari, Balachandran; Zambre, Ajit; Kainth, Jagjot; Selvan, Lakshmi Dhevi N.; Parameswaran, Sowmya; Afrasiabi, Zahra; Krishnakumar, Subramanian; Kannan, Raghuraman; Upendran, Anandhi

doi:10.1039/c8ra06026f

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nucleolin-targeting aptamer was developed with high-mobility group A siRNA, and the high-mobility group A targeting aptamer was developed with a nucleolin antibody, respectively, and both had therapeutic effects on retinoblastoma. 54 …”

Section: Aptamers Applied In Ophthalmology Researchmentioning

confidence: 99%

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Cao¹,

Zhang²,

Xiong³

2023

IJN

View full text Add to dashboard Cite

Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

show abstract

Section: Aptamers Applied In Ophthalmology Researchmentioning

confidence: 99%

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Cao¹,

Zhang²,

Xiong³

2023

IJN

View full text Add to dashboard Cite

show abstract

Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies

Pareek,

Kumar,

Pareek

et al. 2024

Heliyon

View full text Add to dashboard Cite

Development and characterization of DNA aptamer against Retinoblastoma by Cell-SELEX

Maradani

Parameswaran²,

Subramanian

2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Retinoblastoma (RB) is the most common paediatric intraocular tumour. The management of RB has improved the survival and vision with recent advances in the treatment. Improved therapeutic approaches focussing on targeting tumours and minimizing the treatment-associated side effects are being developed. In this study, we generated a ssDNA aptamer against RB by cell-SELEX and high-throughput sequencing using Weri-RB1 cell line as the target, and Muller glial cell line Mio-M1 as the control. Three aptamers were selected based on the number of repetitions in NGS and phylogenetic relationship and evaluated by flow cytometry to assess their binding affinity and selectivity. The dissociation constant, Kd values of three selected aptamers were found to be in the nanomolar range. Aptamer VRF-CSRB-01 with the best binding affinity and a Kd value of 49.41 ± 7.87 nM was further characterized. The proteinase and temperature treatment indicated that VRF-CSRB-01 targets surface proteins, and has a good binding affinity and excellent selectivity under physiological conditions. The aptamer VRF-CSRB-01 was stable over 72 h in serum and 96 h in cerebral spinal fluid and vitreous. With the high affinity, specificity, stability and specific recognition of clinical RB tumours, VRF-CSRB-01 aptamer holds potential for application in diagnosis and targeting RB.

show abstract

Targeting HMGA protein inhibits retinoblastoma cell proliferation

Abstract: A novel approach to target HMGA proteins in retinoblastoma using HMGA2 siRNA–nucleolin aptamer and HMGA aptamer–nucleolin antibody conjugates was developed.

Cited by 4 publications

References 38 publications

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies

Development and characterization of DNA aptamer against Retinoblastoma by Cell-SELEX

Contact Info

Product

Resources

About